Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aptevo Spin-off Receives $20M Emergent Payment | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aptevo Spin-off Receives $20M Emergent Payment

Final payment funds newly-launched oncology and hematology-focused company

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptevo Therapeutics Inc. has received a $20 million payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent last August.
 
Emergent has provided a total of $65 million in cash contributions to fund Aptevo’s operations as a newly-launched oncology and hematology-focused company. Aptevo has a pipeline of commercial, clinical and preclinical assets and a bispecific technology platform, ADAPTIR, focused on the development of immuno-oncology therapeutics.
 
“The achievement of this final payment from Emergent marks another important milestone in Aptevo’s progress,” said Marvin L. White, president and chief executive officer. “With the generous funding provided by Emergent, and a strong portfolio of revenue-generating commercial assets, Aptevo is solidly positioned to achieve our near-term goals. Specifically, these include: capturing increased market share for our newly-launched Hemophilia B therapeutic, IXINITY; generating additional data from our two clinical-stage programs, otlertuzumab and MOR209/ES414; and rapidly advancing new ADAPTIR immuno-oncology candidates into clinical development.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics